Skip to main content

Table 3 Plasma and blood viscosity measured at baseline, 1-month and 3-month in subjects according to therapy

From: Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy

 

Empagliflozin group (N = 20)

Control group (N = 15)

Baseline

1-month

3-month

Baseline

1-month

3-month

Plasma viscosity

1.48 ± 0.09

1.49 ± 0.11

1.52 ± 0.10

1.47 ± 0.10

1.41 ± 0.06

1.46 ± 0.03

Blood viscosity (45/s)

6.80 ± 0.98

7.47 ± 1.79^

7.53 ± 1.05*^

6.59 ± 0.88

6.41 ± 0.69

6.35 ± 0.82

Blood viscosity (90/s)

5.77 ± 0.72

6.11 ± 1.10^

6.29 ± 0.81*^

5.51 ± 0.69

5.35 ± 0.57

5.35 ± 0.64

Blood viscosity (225/s)

4.87 ± 0.57

5.19 ± 0.75^

5.32 ± 0.66*^

4.66 ± 0.56

4.53 ± 0.50

4.98 ± 0.73

Hematocrit (%)

46.5 ± 3.7

48.2 ± 3.8^

49.4 ± 3.8#^

45.0 ± 4.3

44.0 ± 4.5

43.9 ± 4.5

  1. Data are expressed as the mean ± SD; * p < 0.02; # p < 0.0001. General linear model for repeated measures; ^ p < 0.01, t-test for unpaired data vs Control group